Yahoo Finance Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
Analysts on Wall Street project that Novartis (NVS) will announce quarterly earnings of $1.73 per share in its forthcoming report, representing an increase of 1.2% year over year. Revenues are projected to reach $11.5 billion, declining 11.2% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Novartis metrics that Wall Street analysts commonly model and monitor.
According to the collective judgment of analysts, 'Revenues- Established Brands- Afinitor/Votubia - Total' should come in at $83.83 million. The estimate points to a change of -23.8% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Net sales to third parties' reaching $11.47 billion. The estimate suggests a change of -11.4% year over year.
Analysts predict that the 'Revenues- Solid Tumors- Tafinlar + Mekinist - Total' will reach $491.41 million. The estimate suggests a change of +7.3% year over year.
Based on the collective assessment of analysts, 'Revenues- Hematology- Promacta/Revolade - Total' should arrive at $559.80 million. The estimate points to a change of +2.3% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Hematology- Tasigna - US' will reach $191.80 million. The estimate points to a change of -9.1% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Hematology- Promacta/Revolade - US' of $286.35 million. The estimate indicates a change of +3.4% from the prior-year quarter.
Analysts forecast 'Revenues- Neuroscience- Gilenya - US' to reach $47.13 million. The estimate indicates a change of -41.1% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenues- Immunology- Cosentyx - US' will likely reach $686.56 million. The estimate suggests a change of +30% year over year.
The average prediction of analysts places 'Revenues- Cardiovascular- Entresto - US' at $849.61 million. The estimate indicates a change of +20.7% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Established Brands- Exforge Group - US' will reach $3.54 million. The estimate indicates a change of -11.6% from the prior-year quarter.
Analysts expect 'Revenues- Hematology- Tasigna - Rest of the world' to come in at $202.22 million. The estimate suggests a change of -19.4% year over year.
The consensus estimate for 'Revenues- Solid Tumors- Tafinlar + Mekinist - Rest of the world' stands at $277.64 million. The estimate indicates a change of +5.2% from the prior-year quarter.
View all Key Company Metrics for Novartis here>>>
Shares of Novartis have demonstrated returns of -3.1% over the past month compared to the Zacks S&P 500 composite's -1.7% change. With a Zacks Rank #3 (Hold), NVS is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS) : Free Stock Analysis Report
